Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's

Insurer Aetna has made new hepatitis C drugs from Gilead Sciences Inc. preferred treatments for customers with the liver-destroying virus.

Aetna Inc. says it's reached a deal with Gilead bringing discounts for Sovaldi and Harvoni, which have list prices of about $84,000 and $94,000, respectively, for a course of treatment.

Aetna's decision follows moves by two huge prescription benefit managers, Express Scripts and CVS, to wring big from makers of a of hepatitis C medicines that cure nearly all patients, in as little as eight weeks.

Viekira Pak, AbbVie Inc.'s combo treatment, was launched last month at a list price of about $83,300.

Aetna's deal affects customers who get their from an employer or a health care exchange, or just over 10.8 million people.

Explore further

Express Scripts turns to AbbVie in huge hepatitis C deal

© 2015 The Associated Press. All rights reserved.

Citation: Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's (2015, January 16) retrieved 29 November 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors